These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10311615)

  • 1. New pharmaceuticals reduce cost of illness.
    Hansen RW
    CPJ; 1986 Jun; 119(6):318-20, 323-5. PubMed ID: 10311615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of pharmaceuticals--some direction for employers.
    Goetzel RZ; Ozminkowski RJ; Schutt DC
    Empl Benefits J; 2002 Sep; 27(3):31-5. PubMed ID: 12219561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Special report: the value of pharmaceuticals. An "expensive" drug may be the most cost effective.
    Siegelman S
    Bus Health; 1991; [VALUE]():8-14. PubMed ID: 10170908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of illness: United States, 1980.
    Parsons PE; Lichtenstein R; Berki SE; Murt HA; Lepkowski JM; Stehouwer SA; Landis JR
    Natl Med Care Util Expend Surv C; 1986 Apr; (3):1-90. PubMed ID: 10313412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pathways--an evaluation of its impact on the quality of care in an acute care general hospital in Singapore.
    Cheah J
    Singapore Med J; 2000 Jul; 41(7):335-46. PubMed ID: 11026801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How pharmaceuticals cut direct & indirect costs of therapy.
    Levy RA
    Pharm Times; 1985 Dec; 51(12):82-8. PubMed ID: 10311420
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceutical industry overview: optimal drug therapy.
    Blake P
    Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and quality of life of patients with ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the societal impact of acetylcholinesterase inhibitor therapies.
    Winblad B; Wimo A
    Alzheimer Dis Assoc Disord; 1999 Nov; 13 Suppl 2():S9-19. PubMed ID: 10622674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Special report: the value of pharmaceuticals. Better drugs will reduce total health care costs.
    Bus Health; 1991; [VALUE]():15-6. PubMed ID: 10116286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economics of the use of biologics in the treatment of inflammatory bowel disease.
    Cohen RD; Thomas T
    Gastroenterol Clin North Am; 2006 Dec; 35(4):867-82. PubMed ID: 17129818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special report: the value of pharmaceuticals. Misused or unused prescriptions may cost your health plan plenty.
    Bus Health; 1991; [VALUE]():17-8. PubMed ID: 10116287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotechnology: will it break the health care bank?
    McGivney WT
    Physician Exec; 1992; 18(5):35-6. PubMed ID: 10121675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.